Acadian Asset Management LLC Has $148.57 Million Stock Position in Eli Lilly and Company $LLY

Acadian Asset Management LLC grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 150.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 190,596 shares of the company’s stock after acquiring an additional 114,441 shares during the period. Acadian Asset Management LLC’s holdings in Eli Lilly and Company were worth $148,567,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Wealth Preservation Advisors LLC acquired a new position in Eli Lilly and Company in the 1st quarter valued at $27,000. Blume Capital Management Inc. boosted its position in shares of Eli Lilly and Company by 46.7% in the second quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock valued at $34,000 after acquiring an additional 14 shares during the period. IMG Wealth Management Inc. acquired a new position in shares of Eli Lilly and Company in the second quarter valued at about $35,000. TD Capital Management LLC increased its position in Eli Lilly and Company by 129.2% during the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after acquiring an additional 31 shares during the period. Finally, Family CFO Inc acquired a new stake in Eli Lilly and Company in the 2nd quarter worth about $54,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Activity at Eli Lilly and Company

In related news, Director J Erik Fyrwald acquired 1,565 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the purchase, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Daniel Skovronsky bought 1,000 shares of the business’s stock in a transaction on Tuesday, August 12th. The stock was bought at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the transaction, the executive vice president directly owned 137,660 shares of the company’s stock, valued at approximately $87,331,504. This represents a 0.73% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders acquired 4,314 shares of company stock worth $2,766,929 in the last 90 days. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Price Performance

Shares of LLY stock opened at $923.35 on Friday. The business has a fifty day simple moving average of $799.97 and a 200 day simple moving average of $775.40. The company has a market cap of $872.92 billion, a P/E ratio of 60.35, a P/E/G ratio of 1.21 and a beta of 0.43. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $955.46.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping the consensus estimate of $6.42 by $0.60. The firm had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business’s quarterly revenue was up 53.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be given a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

Analyst Ratings Changes

A number of research analysts have issued reports on LLY shares. Guggenheim restated a “buy” rating and set a $948.00 target price on shares of Eli Lilly and Company in a research report on Thursday, October 16th. BMO Capital Markets boosted their price target on Eli Lilly and Company from $930.00 to $1,100.00 and gave the company an “outperform” rating in a research note on Thursday. Cantor Fitzgerald raised their price objective on Eli Lilly and Company from $925.00 to $985.00 and gave the stock an “overweight” rating in a research note on Friday, October 31st. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Finally, Morgan Stanley reduced their target price on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating on the stock in a report on Friday, October 3rd. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average price target of $960.88.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.